Abstract:The majority of patients with non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations inevitably progress in stage despite an initial substantial and rapid response to EGFR-tyrosine kinase inhibitors (EGFR-TKIs). Previous research indicates that hypoxia may be associated with resistance to EGFR-TKIs in EGFR mutation-positive NSCLC. Therefore, the present study regulated the activity of hypoxia-inducible factor-1 (HIF-1) signaling pathway to observe if it is able to alter the sensitivity of lung cancer cells to gefitinib. The present study selected 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole (YC-1) and dimethyloxalylglycine (DMOG) as a HIF-1 signaling pathway inhibitor and activator, respectively, on HCC827 cells. Cells were incubated with different treatments for different durations: A blank control, DMOG, gefitinib, or DMOG and gefitinib combined, for 36 and 48 h; and then a blank control, YC-1, gefitinib, or YC-1 and gefitinib combined, for 16 and 28 h. A western blot analysis assay was performed to evaluate the protein expression levels of HIF-1α and phosphorylated hepatocyte growth factor receptor (p-MET), an MTT assay was used to determine cell proliferation, a colony formation assay was used to investigate the colony-forming ability and a wound healing assay was used to test the cell migration ability. Additionally, Pearson's correlation analysis was used to evaluate the correlation between p-Met and HIF-1α expression levels. Finally, it was identified that gefitinib and DMOG combined notably improve the growth and cell migration ability of HCC827 cells, compared with gefitinib alone. When gefitinib and YC-1 were combined, the inhibiting effect on the growth and cell migration ability of HCC827 cells was substantially enhanced, compared with the control cells. Pearson's correlation analysis revealed that the p-Met expression level had a strong positive correlation with HIF-1α expression levels. Thus, it was concluded that the HIF-1 signaling pathway influences the sensitivity of HCC827 cells to gefitinib. The positive correlation between p-Met and HIF-1α expression levels may be the underlying mechanism of the HIF-1 signaling pathway influencing the sensitivity of HCC827 cells to gefitinib.

Inhibitory effects of gefitinib combined with AG1024 on colorectal cancer cells in vitro

Effect of EGFR/IGFR-1β Heterodimerization on Anti-Proliferative Activity of Gefitinib Against Colon Carcinoma Cells

Effects of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in EGFR-mutated non-small cell lung cancer.

Effects of Blocking EGFR and IGFR-1β Activation on Cell Cycle and Apoptosis of Colorectal Cancer Cells

Combined Inhibition of Insulin-Like Growth Factor-1 Receptor Enhances the Effects of Gefitinib in a Human Non-Small Cell Lung Cancer Resistant Cell Line

Effect of Wnt Signaling Suppression on Gefitinib in Non Small Cell Lung Cancer Cell Lines

Role of GSK-3β Activation in Responses of Colorectal Cancer Cells to EGFR and IGFR-1 Inhibitor

Hypoxia-inducible Factor-1 Signaling Pathway Influences the Sensitivity of HCC827 Cells to Gefitinib.

The Role of Up-Regulation of Integrin Β1 in Resistance to Gefitinib in Non-Small Cell Lung Cancer

Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells

Inhibitory effect and mechanism of gefitinib combined with metformin on EGFR-TKI intrinsic resistant NSCLC H1975 cells

Phosphorylated Insulin-Like Growth Factor 1 Receptor is Implicated in Resistance to the Cytostatic Effect of Gefitinib in Colorectal Cancer Cells

Effects of EGFR Inhibitor AG1478 in Combination with Celecoxib on the Growth of Gastric Cancer Cells

Geranylgeranyl transferase 1 inhibitor GGTI‑298 enhances the anticancer effect of gefitinib.

Inhibition effects of gefitinib on non-small cell lung cancer cell lines in vitro

Interferon-α Reduces the Gefitinib Sensitivity of Human Non-Small Cell Lung Cancer

Inhibition of EZH2 and EGFR produces a synergistic effect on cell apoptosis by increasing autophagy in gastric cancer cells.

BYL719 reverses gefitinib-resistance induced by PI3K/AKT activation in non-small cell lung cancer cells

GLRX Inhibition Enhances the Effects of Geftinib in EGFR-TKI-resistant NSCLC Cells Through FoxM1 Signaling Pathway

1,25-dihydroxyvitamin D3 signaling-induced decreases in IRX4 inhibits NANOG-mediated cancer stem-like properties and gefitinib resistance in NSCLC cells

Relationship between the sensitivity of human colon carcinoma cells to gefitinib and the expressions of Akt and MAPK